TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31721089
Drug: Orlistat twice
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat twice daily for 30 days, then once daily for another 30 days
Study: 18404296
Drug: Preoperative decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative decolonization protocol using mupirocin ointment (twice daily) and chlorhexidine bath (once daily) for 5 days before surgery.
Study: 18404296
Drug: Concurrent control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent control group (patients of surgeons who did not participate in the intervention study).
Study: 28543183
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg)
Study: 7857114
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution and 35% trichloroacetic acid (single application)
Study: 7857114
Drug: 5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% fluorouracil cream (twice daily applications for 3 weeks)
Study: 7112797
Drug: Nitrofurantoin macrocrystals
Normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin macrocrystals 200 mg daily
Study: 27859478
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral motor exercises (Control)
Study: 26255012
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin sodium (LMWHS) 2,500 U subcutaneously, twice a day for 5 days
Study: 26255012
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium 12,500 U intravenously for 24 hours for 5 days
Study: 23140479
Drug: Masked Gabor
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masked Gabor patches presented in the fovea
Study: 23140479
Drug: Masked Gabor
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masked Gabor patches presented in near periphery (6°)
Study: 15545163
Drug: OMC (ome
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.)
Study: 15545163
Drug: OP (ome
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP (ome 20 mg and placebo)
Study: 15545163
Drug: OMC (ome
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.) with NSAIDs
Study: 15545163
Drug: OP (ome
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP (ome 20 mg and placebo) with NSAIDs
Study: 12577391
Drug: Acanthopanax senticosus
Normalized name: Acanthopanax Senticosus (Eleuthero) Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acanthopanax senticosus (AS) treatment
Study: 8400346
Drug: octreotide 0.5
Normalized name: octreotide 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide 0.5 mg three times per day s.c.
Study: 8400346
Drug: loperamide 4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: loperamide 4 mg three times per day p.o.
Study: 2439781
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after discontinuation of active treatment)
Study: 2439781
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of bisoprolol (5, 10, 20 mg)
Study: 2439781
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of bisoprolol
Study: 29540325
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (SGLT-2i)
Study: 18984667
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg daily for 6 months
Study: 21169260
Drug: CAF (Cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (Cyclophosphamide, intravenous doxorubicin, and 5-fluorouracil)
Study: 21169260
Drug: CMF (Cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (Cyclophosphamide, intravenous methotrexate, and 5-fluorouracil) ± tamoxifen
Study: 12690224
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg/kg plus ethanol 0.2 g/kg
Study: 12690224
Drug: Caffeine 8
Normalized name: caffeine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 8 mg/kg plus ethanol 0.4 g/kg
Study: 12690224
Drug: Concomitant thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant thrombolytic therapy
Study: 10663449
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravenous glibenclamide (Gb)
Study: 1531219
Drug: 2g/m2 of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g/m2 of etanidazole administered intravenously after 30 min (group A)
Study: 1531219
Drug: 2g/m2 of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g/m2 of etanidazole administered intravenously after 60 min (group B)
Study: 1531219
Drug: 2g/m2 of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g/m2 of etanidazole administered intravenously after 120 min (group C)
Study: 27839981
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taliglucerase alfa (dose as previously treated with imiglucerase)
Study: 26869678
Drug: PRM‐151 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRM‐151 (recombinant human pentraxin‐2) at doses of 1, 5, or 10 mg·kg(‐1) administered intravenously on days 1, 3, 5, 8, and 15.
Study: 24462229
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT-arm)
Study: 24462229
Drug: Ultra-brief pulse
Normalized name: BRIEF,ULTRA BRIEF LARGE TENA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-brief pulse continuation electroconvulsive therapy (ECT-arm)
Study: 24462229
Drug: No add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: No add-on therapy (MED-arm)
Study: 22823477
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and promotion of target-driven, intensive treatment of multiple risk factors (n = 1678 patients)
Study: 17825197
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment combined with laparoscopy and digital subtraction angiography (group B)
Study: 12088807
Drug: Sodium thiopental,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental, 5 mg/kg (25 microg/kg/min)
Study: 12088807
Drug: Generic propofol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic propofol, 1.25 mg/kg (50 microg/kg/min)
Study: 12088807
Drug: Nongeneric propofol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nongeneric propofol, 1.25 mg/kg (50 microg/kg/min)
Study: 8132701
Drug: Coumarin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin (50 mg daily for 2 years)
Study: 2510561
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg intravenous flumazenil repeated every minute until fully awake (mean 4.5 +/- 2.6 micrograms.kg‐1)
Study: 28568608
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg at bedtime (acute dose)
Study: 28568608
Drug: Flibanserin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 200 mg after chronic dosing (supratherapeutic dose)
Study: 28568608
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg (positive control)
Study: 21272154
Drug: Tolterodine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine treatment for 6 months
Study: 19151286
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of lidocaine 15 mg/mL with epinephrine 5 microg/mL
Study: 2678804
Drug: Ca Heparin
Normalized name: heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ca Heparin (0.5 mgs b.i.b.) + EC
Study: 2678804
Drug: Venoruton (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton (1 g, t.i.d.) + EC
Study: 2678804
Drug: Venoruton (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton (1 g, t.i.d.) after superficial thrombectomy + EC
Study: 17988379
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 2 g before and after intervention
Study: 9388128
Drug: 20-mg lovastatin
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg lovastatin for 6 months
Study: 31232840
Drug: Standard occlusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard occlusive dressing method (hydrogel or alginate and hydrocolloid compounds)
Study: 23380428
Drug: Tizanidine PIC®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine PIC® 4 mg
Study: 23380428
Drug: Sirdalud® 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirdalud® 4 mg
Study: 16941685
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b (1.5 microg/kg) monotherapy
Study: 16941685
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b (1.5 microg/kg) in combination with ribavirin
Study: 14613633
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin (lotion)
Study: 14613633
Drug: Thiabendazole (ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiabendazole (ointment and lotion)
Study: 14613633
Drug: Metrifonate (lotion)
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (lotion)
Study: 9363714
Drug: Follicle stimulating
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follicle stimulating hormone (FSH) therapy
Study: 1389519
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 600 mg/m2 plus leucovorin (LV) 500 mg/m2
Study: 1389519
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 600 mg/m2 alone
Study: 26671307
Drug: Subtherapeutic CPAP
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtherapeutic CPAP (withdrawal of treatment) for 2 weeks
Study: 22304968
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and Alternative Medicine (CAM) treatments
Study: 16275967
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy with magnesium oxide, Lactobacillus acidophilus, and simethicone
Study: 16275967
Drug: Intravenous hydration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration, nasogastric-tube decompression and nothing by mouth (control)
Study: 7630075
Drug: Enteral catheter
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral catheter feeding using Inpitan, ovolact, and hypernutril administered via the nasal passage into the proximal segment of the jejunum starting 5 to 7 days after the operation.
Study: 7630075
Drug: Parenteral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral feeding (Control group).
Study: 2294793
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg every 6 hours)
Study: 28717512
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy for PTSD (DBT-PTSD)
Study: 29188854
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nutraceuticals based on Bacopa monnieri, L‐theanine, Crocus sativus, copper, folate and vitamins of B and D group
Study: 18774567
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg sublingual misoprostol
Study: 14633525
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate solution (25 mL/kg, mean 1565 mL) infused over 15, 30, 45, and 80 min
Study: 10708287
Drug: Abacavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir monotherapy (100, 300 or 600 mg twice daily)
Study: 10708287
Drug: Abacavir/lamivudine/zidovudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir/lamivudine/zidovudine combination therapy
Study: 8415473
Drug: Tianeptine (T)
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (T) 37.5 mg/day
Study: 8415473
Drug: Maprotiline (M)
DrugBank: Maprotiline (DB00934)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maprotiline (M) 75 mg/day
Study: 8415473
Drug: Tianeptine (T)
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (T) with Hormone Replacement Therapy (HRT)
Study: 3533086
Drug: Suprofen syrup
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen syrup 200 mg
Study: 3533086
Drug: Metamizole syrup
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole syrup 500 mg
Study: 17172616
Drug: Pramipexole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole treatment
Study: 19637794
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of meropenem (1.0 g/day over 24 hours)
Study: 19637794
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of meropenem (0.5 g infused morning and evening)
Study: 12466771
Drug: Manipulative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative treatment of the structures of the shoulder girdle in addition to standard treatment by the general practitioner
Study: 12466771
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment by the general practitioner
Study: 26251920
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fish oil/day (540 mg EPA + 360 mg DHA)
Study: 19659504
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg + Amlodipine 5 mg
Study: 19659504
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg alone
Study: 19659504
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg + Atenolol 50 mg
Study: 11314888
Drug: Toothpaste slurry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste slurry (3 g/10 ml water)
Study: 8202902
Drug: Theophylline (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (sustained release preparation, orally, adjusted to achieve blood level above 55.5 mumol/l)
Study: 31464354
Drug: Swallowing speed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing speed for water (measured at 90 mL)
Study: 31464354
Drug: Swallowing speed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing speed <10 mL/s
Study: 29161684
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity CRRT (effluent flow 40 mL/kg/h)
Study: 29161684
Drug: Lower intensity
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity CRRT (effluent flow 25 mL/kg/h)
Study: 17696230
Drug: HD-03/ES (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-03/ES (two capsules twice daily for six months)
Study: 17239273
Drug: Parenteral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral estrogen
Study: 17239273
Drug: Conventional androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional androgen deprivation therapy (ADT)
Study: 15133780
Drug: New therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapy during open-label follow-up phase
Study: 8872767
Drug: Daily consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consecutive administration of 9 million units (MU) IFN‐alpha for 2 weeks and thereafter 3 MU intermittently 3 times weekly for 22 weeks (Group A)
Study: 8872767
Drug: Exclusively intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusively intermittent administration; 9 MU IFN‐alpha twice weekly or 6 MU IFN‐alpha thrice weekly for 24 weeks (Group B)
Study: 3382764
Drug: Prednisolone at
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone at a dose of 5 mg twice a day
Study: 6239689
Drug: Tamoxifen at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen at a dose of 10 mg twice a day
Study: 25920500
Drug: Budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MMX 9 mg as monotherapy
Study: 25920500
Drug: Budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MMX 9 mg as add-on therapy to 5-ASAs
Study: 25920500
Drug: Budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide MMX 9 mg monotherapy in CORE I study extension
Study: 16752263
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg vaginal tablets of misoprostol
Study: 16752263
Drug: One-eighth of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-eighth of a 200-microg oral tablet administered intravaginally
Study: 15701186
Drug: Three monthly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three monthly subcutaneous injections of 3.6 mg of goserelin
Study: 15701186
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of 10.8 mg of goserelin
Study: 30306229
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg E2-valerate
Study: 27496252
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants (control group, Ø3.3‐3.7mm, L11‐13mm)
Study: 27496252
Drug: Mini implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini implants (study group, Ø1.8‐2.4mm, L13‐15mm)
Study: 25287156
Drug: Proteinuria present
Normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteinuria present (P/C ratio >23 mg/mmol)
Study: 25287156
Drug: No proteinuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: No proteinuria (P/C ratio ≤23 mg/mmol)
Study: 20063135
Drug: Remifentanil 1.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.32 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Study: 20063135
Drug: Remifentanil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil doses of 0.25, 0.5, 1, or 2 microg.kg(‐1)
Study: 8624292
Drug: Fixed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed treatment (FT) - 4 full MOPP/ABVD courses
Study: 8624292
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment (IT) - treatment up to complete remission (CR)
Study: 31794566
Drug: Art Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art Therapy (AT)
Study: 22868657
Drug: raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raloxifene hydrochloride 60 mg/day
Study: 22868657
Drug: alfacalcidol 1
Normalized name: alfacalcidol 1 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfacalcidol 1 μg/day
Study: 21575502
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine group (large dose compound Sophora flavescens Ait injection, 20 ml/d, 21 days as a cycle)
Study: 30076946
Drug: Chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group
Study: 21575502
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine group
Study: 10845879
Drug: Droloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene (60 mg/d)
Study: 10845879
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (0.625 mg/d)
Study: 8764787
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (0.75% bupivacaine)
Study: 19137863
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Topical and Retrobulbar)
Study: 19043151
Drug: Cognitive Analytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Analytic Therapy (CAT)
Study: 31849170
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily walking steps for 6 months
Study: 28395364
Drug: Oral Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Paracetamol
Study: 28395364
Drug: Oral Ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ibuprofen
Study: 18837771
Drug: TJ-48 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-48 (7.5 g/d, n=22)